Market capitalization | $127.38m |
Enterprise Value | $104.65m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.55 |
P/S ratio (TTM) P/S ratio | 1.88 |
P/B ratio (TTM) P/B ratio | 0.99 |
Revenue growth (TTM) Revenue growth | -14.61% |
Revenue (TTM) Revenue | $67.64m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:
8 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 68 68 |
15%
15%
|
|
Gross Profit | 65 65 |
15%
15%
|
|
EBITDA | -119 -119 |
11%
11%
|
EBIT (Operating Income) EBIT | -122 -122 |
11%
11%
|
Net Profit | -116 -116 |
13%
13%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Head office | United States |
CEO | Jay Luly |
Employees | 131 |
Founded | 1995 |
Website | www.enanta.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.